Ceftolozane-Tazobactam + Meropenem
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Febrile Neutropenia
Conditions
Febrile Neutropenia
Trial Timeline
Mar 26, 2025 → Dec 1, 2026
NCT ID
NCT06342115About Ceftolozane-Tazobactam + Meropenem
Ceftolozane-Tazobactam + Meropenem is a approved stage product being developed by Merck for Febrile Neutropenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06342115. Target conditions include Febrile Neutropenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06342115 | Approved | Recruiting |
| NCT04238390 | Phase 3 | Withdrawn |
Competing Products
8 competing products in Febrile Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 77 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 84 |
| linezolid + vancomycin | Pfizer | Phase 3 | 76 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |